Regenxbio (RGNX) expects its balance in cash, cash equivalents and marketable securities of $363.6M as of June 30, 2025 to fund its operations into early 2027. This cash runway guidance is based on the company’s current operational plans and excludes the impact of any material payments that may potentially be received from partners or licensees upon the achievement of development or regulatory milestones, or upon the approval or commercialization of product candidates, and excludes potential monetization of a PRV that would be received upon potential approval of clemidsogene lanparvovec.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- RegenXBio: Strong Financials and Undervalued Growth Potential Justify Buy Rating
- Optimistic Buy Rating for RegenXBio Amidst RGX-202 Program’s Promising Advancements and Strategic Safety Measures
- RegenXBio’s Strategic Approach and Promising Outlook Earns Buy Rating
- RegenXBio Positioned for Success Amidst SRPT’s Elevidys Concerns: Analyst Recommends Buy
- BofA expects no changes for Regenxbio regimen after competitor safety issue